A detailed history of Mcrae Capital Management Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Mcrae Capital Management Inc holds 31,880 shares of VRTX stock, worth $15 Million. This represents 3.05% of its overall portfolio holdings.

Number of Shares
31,880
Previous 33,520 4.89%
Holding current value
$15 Million
Previous $15.7 Million 5.63%
% of portfolio
3.05%
Previous 3.75%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$460.0 - $505.78 $754,400 - $829,479
-1,640 Reduced 4.89%
31,880 $14.8 Million
Q2 2024

Jul 24, 2024

SELL
$392.81 - $485.53 $164,980 - $203,922
-420 Reduced 1.24%
33,520 $15.7 Million
Q1 2024

Apr 18, 2024

SELL
$407.69 - $446.08 $320,036 - $350,172
-785 Reduced 2.26%
33,940 $14.2 Million
Q4 2023

Jan 22, 2024

SELL
$343.0 - $410.68 $186,249 - $222,999
-543 Reduced 1.54%
34,725 $14.1 Million
Q3 2023

Oct 17, 2023

SELL
$338.18 - $362.46 $105,512 - $113,087
-312 Reduced 0.88%
35,268 $12.3 Million
Q2 2023

Jul 21, 2023

BUY
$314.42 - $351.91 $72,631 - $81,291
231 Added 0.65%
35,580 $12.5 Million
Q1 2023

Apr 19, 2023

SELL
$283.23 - $323.1 $116,124 - $132,471
-410 Reduced 1.15%
35,349 $11.1 Million
Q4 2022

Jan 20, 2023

SELL
$285.76 - $321.48 $173,170 - $194,816
-606 Reduced 1.67%
35,759 $0
Q3 2022

Oct 20, 2022

SELL
$273.83 - $305.53 $35,597 - $39,718
-130 Reduced 0.36%
36,365 $10.5 Million
Q2 2022

Jul 20, 2022

BUY
$234.96 - $292.55 $1.88 Million - $2.34 Million
7,995 Added 28.05%
36,495 $10.3 Million
Q1 2022

Apr 21, 2022

BUY
$221.42 - $260.97 $6.31 Million - $7.44 Million
28,500 New
28,500 $7.44 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Mcrae Capital Management Inc Portfolio

Follow Mcrae Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mcrae Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Mcrae Capital Management Inc with notifications on news.